FYN as a Radioligand Therapy Target
FYN, FYN proto-oncogene, Src family tyrosine kinase, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, FYN staining is highest in lymphoma (75% of samples positive), glioma (50% of samples positive) and thyroid cancer (25% of samples positive). Clinical status: Clinical-stage (up to phase 2, any modality).
Is FYN a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in lymphoma, 75% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
FYN expression in cancer
Protein expression of FYN across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Lymphoma | 0.50 | Medium | 75% |
| Glioma | 0.25 | Medium | 50% |
| Thyroid Cancer | 0.17 | Low | 25% |
| Neuroendocrine Tumors | 0.17 | Low | 25% |
| Skin Cancer | 0.03 | Low | 8% |
| Colorectal Cancer | 0.03 | Low | 8% |
| Breast Cancer | 0.03 | Low | 8% |
Not detected by IHC in: head and neck cancer, ovarian cancer, melanoma, kidney cancer, bladder cancer, cervical cancer, lung cancer, pancreatic cancer, prostate cancer, gastric cancer, testicular cancer, endometrial cancer, liver cancer.
Is FYN internalized?
Nuclens has not yet extracted internalization evidence for FYN. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
FYN clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for FYN yet. Search ClinicalTrials.gov for FYN trials.
FYN normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See FYN in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
FYN gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: 0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related lymphoma radioligand targets
c-MET (MET) · CD20 (MS4A1) · HER3 (ERBB3) · CD45 (PTPRC) · CD19 · SSTR2 · STEAP2 · CD22
See all radioligand therapy targets in lymphoma.
See how FYN ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.